The cost effectiveness of ivabradine in the treatment of chronic heart failure

June 19, 2014

Source: Heart, 2014, 100 (13) p. 1031-6

Follow this link for fulltext

Date of publication: July 2014

Publication type: Journal article

In a nutshell: This economic evaluation assessed the cost-effectiveness of ivabradine from the perspective of the UK National Health Service, based on the results of the SHIfT trial. Ivabradine is expected to have a 95% chance of being cost-effective in the EU-licensed population using the current NICE cost-effectiveness threshold of £20,000 per QALY.

Length of publication: 6 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.

Advertisements

Cost effectiveness of telehealth for patients with long term conditions

April 12, 2013

Source: BMJ, 22nd March 2013; Correction published 28th March 2013

Follow this link for fulltext

Date of publication: March 2013

Publication type: Research

In a nutshell: This economic evaluation examined the costs and cost-effectiveness of telehealth. 3230 people with heart failure, chronic obstructive pulmonary disease or diabetes were recruited for this telehealth trial. The authors concluded that telehealth does not seem to be a cost-effective addition to standard support and treatment.

Length of publication: 19 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.